M&A Deal Summary

Roche Acquires ARIUS Research

On July 23, 2008, Roche acquired life science company ARIUS Research for 191M CAD

Acquisition Highlights
  • This is Roche’s 6th transaction in the Life Science sector.
  • This is Roche’s 23rd largest (disclosed) transaction.
  • This is Roche’s 1st transaction in Canada.
  • This is Roche’s 1st transaction in Ontario.

M&A Deal Summary
Date 2008-07-23
Target ARIUS Research
Sector Life Science
Buyer(s) Roche
Deal Type Add-on Acquisition
Deal Value 191M CAD
Advisor(s) Aquilo Partners LP (Financial)

Target

ARIUS Research

Toronto, Ontario, Canada
ARIUS Research, Inc. is a biotechnology company discovering and developing the next wave of antibody therapeutics to treat cancer and other diseases. At the core of the Company is a unique, proprietary FunctionFIRST technology platform that generates and selects therapeutic antibodies based on their activity. This antibody generation engine has enabled ARIUS to develop a pipeline of more than 400 antibody drug candidates.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Roche

Basel, Switzerland
Category Company
Founded 1896
Sector Life Science
Employees100,920
Revenue 60.4B CHF (2023)
DESCRIPTION
Roche's corporate headquarters in Basel, Switzerland.
Roche's corporate headquarters in Basel, Switzerland.

Roche is a research-focused healthcare company focused on pharmaceuticals and diagnostics. Roche offers differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche was founded in 1896 and is based in Basel, Switzerland.

DEAL STATS #
Overall 9 of 42
Sector (Life Science) 6 of 29
Type (Add-on Acquisition) 8 of 35
State (Ontario) 1 of 1
Country (Canada) 1 of 1
Year (2008) 3 of 3
Size (of disclosed) 23 of 29
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2008-04-15 Piramed Limited

Slough, United Kingdom

Piramed is a biotech company whose mission is to discover and develop new medicines primarily for the treatment of cancer and immune inflammatory disorders such as arthritis and asthma. Piramed is a leading company in the discovery of highly selective drugs that inhibit different isoforms of PI3-K, enzymes that are increasingly recognised as key players in a wide variety of disease processes.

Buy $160M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2009-03-12 Genentech

San Francisco, California, United States

Genentech is a biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The Company is based in San Francisco.

Buy $46.8B
Mergr

Product

Company

Legal